Abstract
On April 22, 2020, the FDA granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY; Immunomedics, Inc.) for the treatment of patients wit......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
